Halma plc (HLMA) Earnings Call Transcript
November 21, 2024
Earnings Call Speaker Segments
Good morning, everyone, and welcome to the presentation of our half-year results. It's a pleasure to be here and to share a genuinely strong set of results. Before we get into the numbers, though, I'd like to begin by acknowledging the amazing work of everyone at Halma — both as individuals and as a team — in delivering yet another set of record results. I feel enormously proud of how dedicated you all are and of the commitment you keep showing to making a positive difference in people's lives. That is what fuels our ongoing success. So, thank you. Steve will walk you through our financial performance in more detail in a moment. In brief, though, I'm delighted to report record revenue and profit, and we reached a couple of milestones during this first half of the year. Revenue has passed GBP 1 billion, and EBIT has exceeded GBP 200 million for the first time. It's also great to see that our reported performance rests on a solid foundation of organic growth, with double-digit increases in both revenue and profit. Beyond that growth, we've kept delivering strong margins, high returns, and excellent cash generation, which lets us make substantial investments in support of our future growth — both organically and through acquisitions — with M&A momentum carrying on into the second half. This strong performance supports a 7% increase in the interim dividend, which reflects our continued confidence in our future prospects.
What these results do is add another chapter to our record of producing revenue and profit growth that is both strong and compounding. It's really pleasing to see that over 10 years, the compound annual growth rate for revenue and for profit stands at 12%, which is above our KPI. And that was achieved through a stretch when economic and geopolitical events were volatile — take the COVID pandemic, supply chain challenges, and substantial shifts in government and policy. Importantly, taking the longer view, this continuing performance shows what we gain from our sustainable growth model and how much the long-term growth drivers matter, since they underpin growth across our diverse portfolio. Taken together, it was a very successful and pleasing half for Halma. Thanks to how we performed, we're well positioned to make further progress this year and to deliver strong, sustainable growth and returns for decades to come. There's more on this in the second half of the presentation. But first, let me hand over to Steve, who'll give you more details on our financial performance.
Marc, thanks. Good morning, everyone. As you have already heard, we turned in strong results for the first half, hitting record levels of both revenue and profit and extending our history of robust compounding growth. I am happy to report that we are well positioned to deliver for the whole year. In light of the mixed conditions across the markets our company serves, along with other headwinds including FX and higher tax rates, these results once more show the strength of the Halma model. So let us look at how the first half turned out. We achieved strong growth together with high returns. Revenue exceeded GBP 1 billion for the first time, rising 13%. Adjusted EBIT also passed GBP 200 million for the first time, climbing 17%, while the EBIT margin gained 70 basis points to reach 20.7%. Return on total invested capital, ROTIC, came in at 14.3%, an increase of 110 basis points, powered by the strong constant currency profit growth. That figure is a little above the average first half ROTIC we have seen over 10 years and stays comfortably ahead of our weighted average cost of capital. During the first half, we put more than GBP 130 million to work supporting future growth. R&D spending rose 8% to GBP 54 million, equal to 5% of group revenue.
For our companies to keep expanding over the medium term, this investment is essential. It also nicely mirrors the opportunities our companies perceive ahead, and it is encouraging that they remain well invested. In half one we completed four acquisitions — one standalone and three bolt-ons — spending GBP 84 million. Marc will tell you about two additional bolt-on acquisitions made since the end of September, and this week we have also just announced a standalone acquisition. That puts total acquisition spend for the year to date at GBP 158 million. Going forward, the M&A pipeline stays healthy across all three sectors. It is also great to see recent acquisitions adding more than 4% to EBIT growth in the first half. Strong cash generation and a healthy balance sheet make all of these investments possible. So let's examine some of the metrics behind them. Cash conversion of 108% is strong and comfortably above our target KPI. Thanks to that high cash generation, net debt to EBITDA of 1.27 has edged down slightly from the year-end, and that comes after the continued substantial investment. Lastly, our continued growth, high cash generation and strong balance sheet support a 7% increase in the interim dividend, once again signaling our confidence in the future.
Let's dig into revenue a bit more closely. On this slide you can see a bridge to the 13% year-on-year revenue growth. Organic revenue growth came in at 11.5%. Now let's turn to price and volume. The vast majority of that growth came from volumes, which were driven by continued underlying demand and supported by our order intake — and that order intake is still ahead of both revenue and last year. Price increases contributed 1%-2% of this growth, which sits within our typical historical range and is consistent with the guidance we gave previously. Thanks to these increases, the gross margin stayed high and stable, which reflects the ongoing value our products deliver. In the second half, we expect the benefit from price increases to be at the lower end of our historical range. The reason is that we are cycling against significant price increases that many of our companies put through in the prior period. Moving on, acquisitions — including the likes of TeDan, MK Test, and Lazer Safe — contributed 3.5% to revenue growth. There was one disposal, Hydreka, in May this year, and it made a negative contribution to revenue of 0.4%. Lastly, currency was a drag of 1.6% because of the strengthening of sterling. Based on the latest currency rates, we expect a similar headwind in the second half.
Now let's examine revenue from another angle. This slide breaks down how revenue grew by region. The left-hand side shows reported revenue growth, while the right-hand side presents organic constant currency growth, or OCCY. It's encouraging that revenue rose across every region on a reported basis, and in all regions except Europe on an OCCY basis. Keep in mind that, for us, how fast each region grows is driven primarily by demand strength within a particular niche market rather than by geography-specific factors. Turning to the chart on the right, which covers OCCY growth, we experienced very strong growth in the U.S., our biggest sales region. The main driver there was the environmental and analysis sector, E&A, with outstanding growth in the optical analysis subsector. In Europe, revenue fell 1%, as a weak Healthcare performance more than outweighed solid growth in the other sectors. That reflected softness in Eye Health therapeutics, coming after a very strong showing across the prior two years. U.K. growth of 4% reflected a good performance in Safety and E&A, partly offset by a decline in Healthcare. Asia-Pacific revenue climbed sharply, 11% above last year, reflecting strong growth in China against weaker trends a year earlier.
To put that in context, China accounts for roughly 5% of group revenue. Turning now from revenue to profit, adjusted EBIT rose 17.2% at the reported level and 14.8% on an OCCY basis. That is an impressive rate of growth, though it is cycling a fairly soft prior-year comparator. OCCY profit growth outpaced revenue growth thanks to good margin performance in both Safety and E&A, partly offset by a decline in Healthcare. I will walk you through the individual sector commentaries shortly. Turning to acquisitions, they contributed nicely to half-year profit at 4.1%. That was ahead of their revenue contribution and reflects the quality of the businesses we have acquired recently. Disposals had a small positive impact of 0.2%, which demonstrates our continued discipline in capital allocation as we keep reviewing the portfolio. As with revenue, currency was a drag of 1.9% from the strengthening of sterling. Overall, it is pleasing that our performance produced an EBIT margin increase of 70 basis points to 20.7%. That is toward the top end of what we have historically achieved in the first half of the year. This positions us well to deliver our margin guidance for the full year.
Moving on now to the sector commentaries, and I'll begin with Safety. Building on a strong FY 2024, the Safety sector turned in an excellent performance for the half, with revenue up 11% and profit up 20%. That performance was broad-based, since we saw positive revenue growth in every region and every subsector. Revenue grew at 10% on an OCCY basis. That reflected double-digit growth in the U.S. and Asia-Pacific, with growth spread broadly across the subsectors. It also reflected good growth in the U.K. and other regions, while Europe's growth of 4% was more modest. Growth in the U.K., other regions, and Europe mainly reflected a positive performance in the fire safety subsector. In Europe, weaker trends in worker safety partly offset this. Profit was up 20% on a reported basis and up 18% on an OCCY basis, and it was up across all subsectors. I was particularly pleased to see Safety's profit margin expand by 190 basis points. This is continued margin improvement well beyond the recovery from the supply chain challenges of two years ago. The margin benefited from stronger sales growth, more favorable product mix, and good discipline on costs. It also included a good contribution from recent acquisitions, including Lazer Safe, MK Test, and Ampac's recent bolt-on Global Fire Equipment.
And lastly, it was encouraging to observe that businesses in the sector raised their spending in support of future expansion, with R&D rising to 5.7% of revenue. Moving on to the environmental and analysis sector, E&A delivered very strong reported and OCCY revenue growth, each at 27%. Beyond that, revenue increased across every region. Looking at the regional detail on an OCCY basis, the key point is that growth in the U.S. was very strong. That was largely driven by Photonics in the optical analysis subsector, reflecting rising demand for technologies that enable the transformation of data and digital capabilities. In particular, this came from continued successful execution for a long-standing customer. Photonics revenue in half one was, as expected, comparable to the second half of last year. It is anticipated to stay at a similar level in half two. Europe and the U.K. both grew nicely, driven by leak detection solutions within the water analysis and treatment subsector, and in the U.K., a good performance in gas detection within environmental monitoring. Asia-Pac delivered good growth. This chiefly reflected an improved performance in spectroscopy in China, where trends in selected end markets have been slightly firmer, including biopharma and solutions for OEM customers.
On profitability, profit rose 36% on an OCCY basis, and the profit margin recovered somewhat compared with last year, up 190 basis points to 22.8%. That gain reflected the benefit of growth across all subsectors apart from water analysis and treatment. It also took in some recovery in higher margin spectroscopy, which had a difficult first half last year. The sector kept investing at a solid level, with R&D up 9% to GBP 14 million. The lower R&D spend as a percentage of revenue reflected a mixed effect from the recent growth in photonics, which carries a lower R&D requirement. There was also a good contribution from recent acquisitions, including bolt-ons for Mini-Cam and Alicat Scientific. Now let's turn to the Healthcare sector. The Healthcare sector put in a subdued performance, with reported revenue growth of 1%, but a decline of 2.5% on an OCCY basis. By geography, the U.S., Asia-Pacific, and other regions all grew, but Europe and the U.K. declined. If we look at the detail by region on an OCCY basis, there was modest growth in the U.S., reflecting early signs of Healthcare markets improving. In Europe, revenue declined, with a key driver being weakness in the Eye Health therapeutics within the therapeutic solution subsector.
Relative to an exceptionally robust showing across the last two years in Eye Health, this reflects postponements of OEM customer product launches as well as destocking. Revenue in the U.K. came in lower, a reflection of budgetary caution among Healthcare providers. Asia-Pacific revenue posted modest growth. That is mainly due to a gradual rebound in life sciences demand in China. Turning to profitability, the profit margin fell 260 basis points to 20.8%, against a strong comparator in the first half of last year. It was encouraging to see the gross margin stronger, which signals the value in use of our products to our customers. However, that was more than offset by the impact of the revenue decline in higher margin Eye Health therapeutics. R&D spend stayed at a good level, and acquisitions contributed well. It's great to see continued momentum with the acquisition of Lamidey Noury announced this week. Moving now to our cash flow performance, this chart summarizes the group's cash flows for the first half. I'll highlight just three items: working capital, acquisitions, and pensions. I'm really pleased to see how our focus on working capital across the group is bearing fruit. That produced an actual working capital inflow despite the strong growth in the half.
That's also what's driving our robust cash conversion of 108%, which is comfortably above the 90% KPI target we set. The net spend on acquisitions largely reflects the four acquisitions and one disposal completed during the period. As we've observed in this half year, those acquisitions are going to provide incremental EBITDA in periods to come. And finally, pensions. Although this isn't a major item for us, it's worth pointing out that in September we bought buy-in policies covering the group's two main defined benefit schemes. There's no impact on the P&L or cash flow, and it carries the benefit of lowering the principal risks tied to those two schemes. Let's now move to our financial KPIs and how we've done against them. Taken as a whole, this is a strong set of results. That's particularly the case given the varied market conditions our companies are encountering in their end markets. We have met or exceeded every one of our financial KPIs. In short, we've delivered strong growth at high margins, a good profit contribution from recent acquisitions, profit growth that produced a strong EPS performance despite adverse FX and tax movements, cash conversion well over 100%, companies that remain well invested, and return on total invested capital of 14.3%, significantly up from last year and well above our weighted average cost of capital.
Those high returns and robust growth, combined with a prudent approach to risk, mean the group keeps generating substantial value for shareholders. Turning to my final slide, which covers guidance. Given how strong our first half performance has been, we are well positioned to meet the guidance we already have in place for FY 2025. Although conditions continue to differ across the end markets of our individual companies, for the full year we expect to deliver good OCCY revenue growth and an adjusted EBIT margin of around 21%, in the middle of our target range. Group order intake gives additional support here, since it remains ahead of both revenue in the year to date and the comparable period last year. All in all, we are well set to make further progress over the rest of the year. With that, I'll hand you back to Marc.
Thanks, Steve. It's great to see how well we performed against our KPIs during the first half. These strong results came from disciplined execution of our sustainable growth model. In this section of the presentation, I'll focus on three elements of that model that were essential to our first-half success and that will help Halma deliver compounding growth along with high returns over the long term. The first is the deep understanding our companies possess of the markets they serve. That understanding lets them pinpoint the biggest challenges facing our customers and innovate to address them. To illustrate this, I'll concentrate on the positive difference these solutions make in people's lives, and it is that impact, inspired by our purpose, that we continually seek to expand. It serves both as a major source of motivation for our people and as a foundation for our financial results. The second is the considerable advantages that flow from our diversified portfolio of businesses — a portfolio that provides us not only with excellent opportunities for growth but also with resilience against shifts in individual markets. And as you will hear, the acquisitions completed so far this year have strengthened those advantages. And third, talent and culture, both of which are vital to how we perform.
Our devolved and autonomous model depends on having talented people near their customers, focused on delivering in their markets. So recruiting, developing, and retaining the very best people is critical. And we also know there are huge benefits from collaboration and learning across our companies. So three elements, all of which matter to our growth: really understanding our markets, having a great diverse portfolio of companies, and a fantastic team working together. That day, I went to work almost four weeks pregnant. Akshina is one of our fantastic nurses. We just got to chatting, seeing how she felt. Doctor Jeff said that you look so weak. Something was off. Our team felt that if she continued on, the likelihood of having a problem with the baby was high. You can imagine she was anxious, but we were able to calm her down, and we put her on fetal monitoring. In her case, she was doing fine until there were fetal heart rate changes. That was when we took her in and did a C-section. We were able to act very rapidly, and this was a result of monitoring her. I do believe that her baby probably would not be here if it wasn't for PeriWatch.
A tiny new person has come into my world. Someone capable of bringing me joy. Winter's first day, it was. My cousins phoned me, asking me to relight their boiler. I head down to attempt to get the boiler going, and it wasn't combusting correctly. That meant it wasn't venting correctly, either. With the boiler running, I felt extremely sick, and my head was pounding badly. Carbon monoxide is a killer that gives no warning. It's invisible. There's no taste to it. No smell to it. I picked up my tool bag, then I picked up my Sensit, and the moment I came near the basement door, it already read 1,000 parts per million of CO. And I'm thinking, we may have an issue here. A raised carbon monoxide reading would usually sit at about 35 parts per million. It can turn extremely toxic extremely quickly. We evacuated everyone. It was completely horrifying. I'd like to express my gratitude. My cousins weren't the only ones they rescued. They rescued all of us. Every single day, they save lives. What a wonderful video. Two truly inspiring illustrations of our purpose being carried out. And the impact our companies have on the lives of people like Akshina and Chelsea and Chris is something we can take real pride in.
What underpins their growth—and my confidence in what we'll deliver as a group going forward—is our company's capacity to take on some of the most fundamental challenges in the world. Let me unpack that to demonstrate how we view this crucial connection between purpose and performance. Beginning at the top right: our purpose pushes our companies to come up with those life-critical solutions for customers—solutions that carry high value thanks to their positive impact and the complexity of the problems being solved. Going clockwise: achieving that requires our companies to understand deeply the markets where they compete. That's exactly why our operating model matters so much. Within every one of our companies, we have dedicated leadership and commercial teams whose entire focus is their market niche. As a result, they stay close to customers and gain deep market insights that let them spot opportunities and threats alike. The autonomy our org model provides then enables them to be entrepreneurial and agile in identifying shifting dynamics and answering with fresh innovative solutions. And simultaneously, they gain from the collaboration and support on offer as part of our wider global group.
Later on, I'll return to the topic of collaboration and how powerful our network is. The video also highlights a couple of things about how we pick end markets, and you can see that on the left side of the slide. The markets we select have strong, long-term growth drivers, rooted in solutions to problems that are both fundamental and expanding. Two excellent illustrations appeared in the video: the demand for improved Healthcare and for clean air for everyone. Those are worldwide challenges that will only grow over the longer term, which gives us meaningful opportunities for growth in the future. What's more, tackling these challenges lets us achieve strong margins and high returns. And lastly, the markets where we choose to operate are resilient in a fundamental sense. A lot of our products are non-discretionary or recurring — whether because the law or regulation requires them, or just because failing to use them carries too high a cost. That bolsters our resilience, and our diverse portfolio reinforces it further — diverse across end market, geography, and technology, for instance. This lets us keep investing right through short-term cycles in individual markets, and it also underpins how consistently we deliver over the medium term. So it should come as no surprise that organic growth stays our first priority and top priority when it comes to allocating capital.
So, if those are the kinds of businesses we're after in the portfolio, let's turn now to how the portfolio has grown since the start of the year, done through M&A that's disciplined and aligned with our purpose. And I'm happy to say that our positive M&A momentum has carried on through this year so far. As I noted, one advantage of our model is the ability to keep investing across every one of our sectors, whatever the varied conditions in end markets. As Steve told you, we've completed 7 acquisitions since the year began, spending a total of GBP 158 million. Let me spotlight 3 acquisitions, one per sector. Every one of them centers on long-term growth trends and shows well how M&A lets us move into new and adjacent markets while also broadening positions we already hold. MK Test, supporting the energy transition and growing our presence in high-voltage electrical testing following the recent acquisition of WEETECH. Hitzel, expanding Mini-Cam's capabilities and helping ensure clean water and prevent pollution. And, as Steve mentioned, only this week, Lamidey Noury in minimally invasive surgery, adjacent to our existing presence in diagnosis. A great acquisition helping to deliver improved outcomes for patients and driving excellence in Healthcare.
It's also encouraging to see, as the bottom of the slide shows, that a growing number of our companies are turning to bolt-on acquisitions as a way to execute their long-term growth plans — and of the seven acquisitions made during the year, five were bolt-ons. As we look ahead, our pipeline remains healthy, and our leadership teams, the MDs of our companies, and our dedicated M&A resources are actively chasing opportunities within their markets so we can grow and diversify our portfolio further. Moving now to the third and last area I want to cover today: our talent and culture. At this point last year, I talked about how much agility matters — a vital asset for success in a world that keeps changing quickly. Today, my focus is on the value of our collaborative culture, which is a major competitive advantage across our portfolio of companies. Let's use video once more. This clip came from our recent Global Accelerate event, where we gathered all of our company leaders so they could build relationships, exchange best practices, and collaborate. Welcome, everyone. It's fantastic to see you all together. It's an eye-opener to find out what we are now part of, because for a long time we were an SME, or a small business, fighting our own fight, and now realizing we're part of a larger support structure, with people in a similar position to us — that's helpful, and it's certainly something we're going to take back to the rest of the team and really bring to light what we are now part of.
Honestly, I’ve never experienced anything quite like this before, and I’ve been in business for a few years now. What makes it so great, I think, is that you pretty much immerse yourself in the Halma ecosystem. When I look across Halma, there are so many points of contact and so many possible areas for collaboration. As a business leader, we share challenges with other business leaders. We operate in regions that are the same as other businesses here. Being able to work with other leaders and talk through those challenges and share and compare notes and identify ways that we can all work together better is really the benefit for me of this event. I think the relationship that we build here is so important because there’s the opportunity to just then pick up the phone. And now there is a personal connection. And I think, you know, we talk about the unfair advantage that Halma has with all the opcos. And it’s so true, but it’s up to us to tap into that, right? It’s not to look to the group to set it up for us, but it’s really for us to actually build that bridge to each other. I like the way that people connect to each other.
Conversing with anyone here is really easy. There's hardly any hierarchy at all, so it doesn't feel hierarchical. Having connections to people is a really good thing. Each time I leave an Accelerate, I understand what Halma will be seeking over the coming couple of years. And the way they do it is really nice, but it lets us say, here are the things we have to make sure we're covering. These will be the new areas we want to grow into, not on the business side, but in how we grow and where we play. For me, the biggest value is connecting with the various leaders. The people I meet really impress me, and I'm also hugely impressed by the innovations we have. I was just talking with someone, saying it's incredible how much small companies are doing such a positive impact on the world. Another great video. It's fantastic to feel the energy from our leaders and so many themes that I could pick up on in just that short video. Melissa's comment that there are so many areas of collaboration that are possible, and this might surprise some of you. After all, our companies operate in different market niches and sectors and different countries, but despite their diversity, their needs as leaders of entrepreneurial companies are often very similar.
What are the ways we can expand internationally, go digital, deliver results in the near term, and put money to work for the future? How do we bring in and keep top talent, to mention only some of them? If you're an MD or a board member at a Halma company and you have a question, you can feel fairly confident that somebody within what Jason called our support structure will know the answer. Naturally, that demands an open culture — one in which, as Alma put it, talking to anyone is very easy, with very few layers and no hierarchy. All of these are things that, as we've expanded, we've had to strive hard to preserve. Instances include events such as Accelerate, and also growing our people by handing them fresh challenges and experiences across different companies, different sectors, and a range of geographies so they're prepared for their next role. During the past six months, more than a hundred of our leaders have completed our leadership development programs. That provides us with a robust pipeline of leaders able to be promoted from within. Indeed, one of the value propositions we offer to founders and owners is frequently that they require a successor — somebody capable of steering their company through the next stage of growth.
And through growing talent from within who can step into these opportunities, we can feel confident about a seamless handover when that moment arrives. In fact, we've recently seen two excellent instances of exactly that, with founders followed by capable, thoroughly prepared people. Both of them had taken part in several Halma development programs, having begun their careers years back in our outstanding graduate scheme, the Catalyst program. And that talent mindset shows up right across the whole group, from the PLC board all the way to our individual companies. We devote considerable time to grasping what our companies specifically need and to making sure we create a culture and environment where everybody can perform at their very best. And I believe that came across in Rob's remarks about how we grow and where we play, the value we can contribute and how we as a group can tackle broader themes and put investment into particular growth areas to help our companies deliver their own growth strategies. And all of that together underpins what Caroline described as an unfair advantage for our companies in their markets, which I see as how companies do better as part of Halma than they would on their own. So in summary, it's been a highly successful half year.
The basis for that achievement is our model of sustainable growth. That covers the disciplined decisions about where we put capital, organically as well as inorganically, in niche markets whose long-term growth drivers underpin compounding growth and high returns; the advantages we get from a diverse portfolio of businesses; the agility built into our org model, which places great people near their customers with the autonomy to make the best decision for their company at that moment in time; and what we invest in our people and our culture so we can deliver against our ambitions. For these reasons, I believe we are well positioned to make further progress this year and for decades to come. Thank you. We'll now take your questions. There are two ways you can ask questions. You can either raise your hand using the tool at the bottom of your screen, and I'll invite you to ask your question verbally, or you can type your question, which Steve and I will read out and then answer. So looking at the screen, our first question comes from Andrei. So Andrei, we'll start with you. Good morning. Thank you very much for taking my questions.
I'll take two. I'll handle them one by one. First, can you walk us through what happened in the photonics business that came in much stronger than expected during the second half of last year? From what I understand, deliveries in the first half of this year have matched that second-half level. What should we expect for the second half of this year? And then, thinking about it over the midterm and stepping back, what kind of structural growth potential does that technology application have from here? Yeah, thanks, Andrei. I'll take that question. As you mentioned, it's a fantastic achievement by one of our companies — a business that had GBP 4 million in revenue back in 2011. So it's a great example of a business scaling up within the group. And we did see that exceptional growth during the second half of last year. As a reminder, this is a relationship with a customer that we've now had for over 10 years. It was really pleasing to see that ramp-up in terms of them delivering their strategy and the role that we play in it. So we're really pleased to have seen the ramp-up. And it's just as pleasing to see that continue at that high level through the first half of the year.
Looking ahead, I should remind everybody once more that this market is extremely dynamic. Our forward visibility isn't especially strong. That said, we've built a very solid relationship with the customer over the course of many years. So sitting here right now, guidance has already been provided regarding those elevated levels continuing through this year's second half. Then, looking toward next year's first six months, the growth I see is roughly in line with the group's KPIs for revenue growth. Great, thank you. My second question concerns the pipeline for acquisitions. Nearly GBP 160 million of capital has already been committed to acquisitions, as Steven mentioned. Can you share anything about how that pipeline looks for the second half? Of course, predicting acquisitions is always difficult. And broadly speaking at present, does activity feel like it's heating up relative to six to 12 months ago, is it at a more steady level, or are there any indications of cooling? Yeah, as you said, Andrei, pinpointing exact timing is difficult, given our strategy and our approach to M&A and the fact that we seek those fantastic businesses in those niches that solve real-world problems and are underpinned by long-term growth drivers, frequently privately owned.
To put it really simply, what we're attempting to do is acquire companies that are not on the market. Because of that, forecasting exactly when we'll get a sale across the line is quite hard. Having said that, we do have a robust pipeline, as I mentioned, supported by those long-term growth drivers. We've put substantial investment into the group when it comes to our capabilities, and that investment continues. And the team is definitely kept busy right now. We have the financial firepower available. As for what we're seeing going forward, we need to ensure we keep up our disciplined approach regarding purpose, market, future growth, and returns. But having said all that, it's excellent to see the momentum. The pipeline appears robust. On the broader activity in the market, chiefly our largest competitor is in fact the owner's choice about whether to sell. In the areas where we do find ourselves facing private equity, facing other funds, we aim to steer clear of auction processes. But where we are seeing that, perhaps there's been a slight uptick in activity. Yet as I mentioned, our strategy stays the same. We're seeking out fantastic businesses that are privately owned, and providing them a home for their business inside the Halma group.
Great, thanks a lot. Andrei, thank you. I notice Jonathan — Jonathan Hurn — has his hand raised.
Alright, folks, is my voice coming through clearly?
That's right, Jonathan.
Yeah. Yeah. So, uh, good morning, and thanks. I've actually got three questions, if that's alright. The first one stays on optical analysis, but shifting to spectroscopy this time. Clearly that's a high-margin area for you. You're seeing a recovery in China, but could you speak to what's happening in the other regions around the world in that space? That was question one. Question two is about Healthcare and what lies ahead. How should we think about it in terms of the shape of the recovery? Obviously, if we look at H2 last year, that's a fairly weak comp for you in Healthcare. Do you believe Healthcare can get back to growth in the second half of this year? And what sort of magnitude do you think that could be? Then the third and final question is on safety. Obviously, really strong first half margin performance there, roundabout level, sustainable going forward. Those are the three things.
Sure, thanks Jonathan. So, I’ll have Steve start off by addressing the first item, which is about spectroscopy.
Thanks, Jonathan. That's a good question about spectroscopy. Honestly, what I'm glad to report is that we're observing a recovery in spectroscopy that is improving and what I'd describe as slow to modest, and that's across the board, not only in China. We singled out China simply because it was one of the main dynamics behind the growth we saw in Asia-Pacific. But Spectro has been recovering. As you know, it's a high-margin business, so it's an important piece of the E&A portfolio. So we would expect that to keep moving forward. So when we look at the E&A portfolio as a whole, we would expect the margin to improve a little in the second half, given where we're heading. But as far as spectroscopy goes, I think it's heading in the right direction.
Then, Jonathan, regarding your second question about Healthcare and especially the forward outlook: as you mentioned, during the first half of the year—and with some carryover from the tail end of last year—demand across the broader Healthcare markets has been softer, which is well documented. It was encouraging during the first half to observe a modest recovery across a number of end markets within the portfolio. You can definitely see that happening in the businesses based in the U.S., so there is some recovery visible there. But as Steve noted in the presentation, a decline in our ophthalmology therapeutics subsector offset that. To be clear, that came after two years of really strong growth in that business. So seeing that decline—a mix of destocking and, in fact, also driven by delays in OEM product launches—was a situation that genuinely reflects the portfolio. So we've seen those ups and downs. We've seen some recovery, and then we've seen some phasing of downturn. Looking ahead, I think it's fair to say we expect a level of recovery in the second half, but we certainly aren't sitting here expecting a heroic bounce back in Healthcare, which I think aligns with what you will have heard from others as well, and then Safety, Steve.
Would you like to address the margin?
One more point on Healthcare: with iHealth Therapeutics, we operate multiple businesses in that area, and the unit working directly with surgeons continues to show very robust demand. So a shortage or some structural shift in our demand picture isn't something that worries us. We believe our positioning over the medium term is quite strong. On Safety, you're correct. Historically it's a high-margin area for the Safety sector. It's far removed from where we stood in FY 2023, when supply chain problems were affecting us. We've come out of that, and we're now at a high level, which we view as sustainable. Looking at gross margin levels, they appear strong — and what's behind that? It's stronger sales growth. It's a more favorable product mix. We're seeing solid cost discipline, and we've completed a number of accretive acquisitions, such as Lazer Safe, MK Test, and GFE. So taking all those factors together, we believe this margin is sustainable. One caveat I'd offer, though it's further down the road: given the growth Safety has managed to achieve, I think at some point we'll likely need to reinvest to some degree in additional capacity, but I believe that lies further down the road.
That's a solid margin, and yes, I believe it can be sustained.
Thanks. That’s excellent, everyone. I really appreciate it.
And then I’ll turn it over to Max, since I can see your hand is raised. Yep, thanks. Good morning. I’ve just got 2 questions. First, on cash conversion — clearly a very strong start to the year and a very strong first half. Could you share some thoughts on how you’d expect that to unfold in the second half? Would you expect some normalization to below your targeted cash conversion level, or should we think you can remain above that 90% level and deliver a better overall outcome for the full year? Okay, Steve, do you?
Sure, Max, I’m glad to address that. No, honestly, we’re very happy with how the first half went. I believe it shows the broader emphasis we place on returns and on working capital levels, and that is what comes through in these results. I think you’ll also see us exceed the 90% KPI target during the second half. So that is encouraging. One thing driving some of the cash conversion is that inventory days are getting better. Debtor days are improving too. So there’s strong attention to this throughout the group, and we’ve approached it in a Halma-style way: we’ve spoken with the businesses about what matters and what the main drivers are, and then they take that away and carry it forward. So I do expect that we will be above the 90% in the second half. I wouldn’t want you to read that as meaning we should change the medium-term KPI of 90%, because we are a business that invests for the long term. But clearly, the focus we have right now means that, for this year, I think we will be above the 90%. So there won’t be any kind of reversion to 90% because of some underperformance in half two.
That's not how I see it. Perhaps a brief follow-up regarding Safety. Clearly, that division has picked up pace organically during this year, and few kinds of businesses are experiencing acceleration. So obviously, many different businesses sit in there, but all of them are geared toward safety. Could you discuss whether you believe some reason exists that the actual end market is speeding up, or would you attribute this more to how the individual sub-businesses inside that unit have each performed?
Yeah, I think it's more the second one, though I'll return to what's fundamental about the markets we've chosen to compete in. We intentionally operate in those niche markets, solving high-value problems, frequently regulated, and supported by long-term growth drivers. So over the medium term, throughout the whole portfolio, we anticipate that each of our businesses will be capable of delivering that compounding, continuous growth and high return. So there's always phasing when it comes to a portfolio. You'll have stretches where everything is up. You'll have stretches where things are challenged. But certainly, over the medium term, these are excellent markets to be in, and they support our confidence going forward across the group and within the sector itself. Thank you very much. That's great. Thank you, Max. So I've got. I'll just pick up. I've got a couple of questions in the text. First, from — actually, they're all from Stefan. First one, Halma is to some extent U.K.-centric. How will higher NIC costs affect the company? I guess I can pick that one up. As you say, Stefan, we are listed in the U.K., but again, give a little bit of context.
Roughly 14% of our revenue comes from the U.K. About 30% of the workforce is there as well, and the head office is here too. I suppose the main point on that is that, from a materiality standpoint, it isn't material to the group — under 1% of our profits. Having said all that, the individual companies — and I return to the agility point — will work through the right actions for their business. They clearly operate in high-margin niches, as we just discussed. The budget won't be material on its own, but we'll depend on those businesses working it through as we go forward. I think, Stefan — and tell me if I'm wrong — but we've addressed your question regarding the Healthcare sector, regarding trading and the outlook ahead. And your third question concerns M&A. Purchase multiples have declined this year compared with the previous three years. Does that mean acquisition multiples are broadly declining? Picking that up, the straightforward answer is no. We aren't seeing any reduction in multiples. We acquire high-quality businesses with high-quality margins, and those command a particular level of multiple. What I'd say is that it's somewhat risky, given where some of the end markets we've all been operating in have been — and you've seen this across our portfolio — to treat multiples as a single indicator.
You might be coming off a 12-month stretch in which you saw a trough or, in fact, a year of recovery. So on the whole, we're definitely not seeing anything that suggests multiples are broadly declining, but conversely, we aren't seeing a meaningful uptick either. But I return to that point: we are purchasing good-quality businesses in which we hold a high level of confidence regarding their long-term compounding growth. Okay, back to raised hands. So I can see Rory, your hand is up.
Morning, Rory from Oxcap here. Am I coming through okay?
Yeah.
Thanks a lot, and I appreciate the chance to ask my question. Morning, Steve. Morning, Marc. Marc, I believe this one's directed at you, and it concerns M&A. When we look at the bolt-ons, you're completing somewhat more bolt-on deals at the company level. I just wanted to ask, how do you make sure those deals are, in a sense, sourced and executed consistent with, in a sense, group priorities and group, in a sense, criteria for M&A? Do you establish fairly strong guardrails around the operating companies, or is there somewhat more, in a sense, leeway for them to go out and find deals that perhaps you wouldn't have seen landing on your desk previously?
Yes, thank you, Rory. As you mentioned, it's great to witness the momentum in bolt-ons as our individual companies grow larger and gain the capacity to use M&A to deliver their growth strategy. So that momentum coming through is a positive thing, and one would expect it to keep going in the future. Regarding governance on the deals, I suppose, first, in our decentralized autonomous model, we have excellent people close to their markets with genuinely strong insight into the growth drivers in those markets. So to some extent, having that in-depth knowledge and the insights of our leaders who operate in those markets day in, day out de-risks it. Having said all that, if you like, the governance and control around M&A is exactly the same for any deal. Fundamentally, our divisional chief exec will take the lead on acquiring the company. They will serve as the chair on that individual company in this instance. That same DCE will then chair the company with the bolt-on post-acquisition and be responsible for delivering that future growth, so that's in place from an approval and authorization standpoint. Again, we'll come up through the group.
The sector chief executives are going to review and approve it, and Steve and I sign off on every M&A deal across the group, and then anything above 10 million actually goes to the main board — but just to be clear, that isn't some kind of investment committee. All of us are deeply engaged at the early stages, really hashing out what's happening in the market and getting comfortable with the future cash flow, so in the end, I'd say it carries lower risk than standalone deals, but at the same time it's value creative for us.
That's quite useful, thank you very much. And I notice—thanks, Rory—I notice Bruno has his hand raised. Appreciate you taking my questions. First off, two quick ones regarding the contribution from acquisitions. For the half, the contribution margin on acquisitions looks somewhat lower in H1, considering the financial profile of the assets you picked up recently—I believe 23% at group level. And for Healthcare, 17%, where, for instance, I think Rovers' margin was incredibly rich. So I suppose the two questions are: why was that contribution margin a bit lower? Were there certain investments you needed to make, or did any of the markets for the acquired assets soften downwards? And second, can you offer any guidance on the contribution from acquisitions for the full year?
Alright, Bruno, I’ll take those. On the acquisition side, when we initially bring a company into the group, we frequently have to make extra investment. That’s the reason you’ll notice part of the reduction coming through. So what you’re expecting won’t be exactly what you see. It’s more that than certain markets falling away after joining the group. I think that is the main driver. Regarding what we expect from M&A and the contribution it will deliver, looking at it on a revenue basis, I think for the full year it will be somewhere around just over 3%. Then if I consider the disposals we have completed, I think that adds up to roughly 3% overall, 2.5%-3%. So those are the figures in our modeling, and I think they are very accurate. Okay, understood. And just finally, apologies if this has been partly covered, but a question about the softer market development in ophthalmology and what it means for margin, especially as we think about H2. So how long do you expect the destocking to last? Are we basically past it today, or does it continue into H2?
And when we think about that Healthcare margin in H2, are you doing anything to offset that softer top-line development? So can you give us any color, I guess, on how that margin trends in H2 and what you expect?
That's a fair question. It's quite interesting to examine the portfolio effect within Healthcare. Revenue is lower by roughly 2 to 2.5% during the first half, yet the margin has fallen by a larger amount than that. Part of that reflects—as you correctly identified—the mix impact from the high-margin Eye Health therapeutics segment. Another part comes from a bit less leverage as revenues decline somewhat. For the second half, we aren't building in anything heroic regarding a recovery. I believe the difficulties in Healthcare are well documented. So we expect a degree of improvement, and therefore some leverage will return. That means there will be a measure of margin improvement. Regarding Eye Health therapeutics, based on what we observe, perhaps a modest gain in the second half, though we aren't factoring in anything meaningful for the second half. So I'd say it's more in FY 2026 that I would look for that to recover, especially when we refer to the European-based business. As I mentioned, our remaining Eye Health businesses are performing strongly, since underlying demand is solid. So we simply have to get past the delay in product launches among certain OEM customers along with some of the overstocking.
But I think this is an FY 2025 phenomenon. That part is very clear. Thank you. Thanks, Bruno. I’m just looking at the screen here. So Margaret, I can see your hand is up as well. Yes, good morning. I hope you can hear me. Thanks for taking my questions. I have only two, if I may. Just going back to the first question about the pipeline, could you give us some indication? You’ve mentioned before that it’s 600+ companies, but during the last six, seven, eight months, how many of those are new companies entering the pipeline? How much traction is there in refreshing that pipeline? If you could give us a little commentary on that, and then the second question is it’s very pleasing to see the ROTIC trend move higher, but structurally, as you bring in higher-margin businesses, would you expect to hold a higher level of normalized working capital than you have historically, and so regarding recovery of that trend, what should we be thinking about in terms of those moving parts there? Yeah, thanks, Margaret. I’ll take the first one regarding the pipeline. As you say, it’s running at anywhere between sort of 600 or 700.
On the question of how many of those are new versus how many move through the funnel, it's tough to give a precise figure, but new companies are definitely always entering at the top of the pipeline — whether through insights from our company MDs, through insights from attending trade shows, or from our central teams carrying out market mapping. So my estimate would be that we bring in 50 or 100 new companies and move them through at the pace we're reviewing. But again, I return to that point: it's really hard to oversimplify our approach when we're building relationships with these companies, at times across 10, 15, 20 years, rather than necessarily working through pipelines the way you might see at more traditional M&A companies. And Steve, did you want to pick up the one?
Yes. Thank you for asking about returns, capital employed, and the effect of M&A. On the whole, we're quite happy with the progress we're making on capital returns. We examine it through several lenses and several measures. Return on capital employed for the first half is up almost 7 percentage points against the same time a year ago. ROTIC has risen 110 basis points versus this time last year. And viewed through a CFROI lens, we're up substantially too. So it's encouraging to see that. On acquisitions, obviously, when we bring in a new business, that will add to our working capital, no question. But when we look at those businesses and we're evaluating a target, we're examining its returns performance. We're also examining its margins performance to judge whether we think this is a Halma-type business. So when the business comes into the fold, although it may create some drag on the return on capital for the first three or four years, I don't expect it to have a massive impact on the working capital. What was interesting to us over this last six months is that overall, our working capital is down despite the M&A.
That comes from the emphasis our companies have placed on receivables, stock, and payables, among other things. So working capital will rise as time goes on, but what we want is for our businesses to be efficient when viewed from a balance sheet standpoint. And they understand that. And they have incentives around that too. So there's a remuneration plan with a capital charge incorporated in it. Remuneration happens on an EVA basis. Yep. That's very useful. I appreciate it.
Thanks, Margaret. And then just taking a look at the screen here. So Mark — Mark Davies Jones — I can see your hand is raised.
Yeah, thanks, Marc. That's a broad question — and maybe a slightly impossible one — but clearly the US is now your biggest market by a fair margin, and it's also what's driving growth. There have been some interesting political shifts over there. Looking ahead, are there any spots where tariffs — especially those coming from Europe into the U.S. — could hit you, or anything we ought to be especially worried about, given your emphasis on the E&A business and on regulatory drivers, where some kind of pullback in state support would pose a threat? I always enjoy a broad and impossible question.
Thanks, Mark. I'll take it from there. I believe the key is really to return to the fundamental components of how our model works. At the center of it all is a strategy that keeps our companies near their customers. So across the portfolio, it's very much local to local. To add a bit of detail on that, more than 70% of our revenue is, so to speak, local to local within the region. And in the U.S. specifically, that figure stands at roughly 90%, just to provide some context, from a revenue standpoint. So I think that starting point of having businesses that sit close to their customers leaves us in a comparatively strong position. Then, naturally, you consider the fact that we operate in those niche, high-value markets, which are supported by the long-term growth drivers. That gives us a strong margin, thanks to the value we're creating and a certain degree of pricing power that we apply appropriately, and then I suppose we gain further from the agility built into the model, so again, a decentralized autonomous model. Every individual business has that autonomy and that capacity to make the right decisions for its business, for its customers, for its supply chain, so when you bring all of those things together, I think we're comparatively well placed.
Then perhaps a few additional things deserve mention. Clearly, from the more recent U.S.-China tariffs we now possess the lessons and experience of how to handle them, which lets us distribute best practice throughout the group. And then, fundamentally, it comes back to this: we remain on track to deliver a 22nd consecutive year of record profit growth. A great deal has changed across many areas during that stretch. That genuinely mirrors the points I have just described. What do we want from governments? We want that emphasis on tackling the long-term challenges: clean air, clean water, health infrastructure. We want frameworks that encourage investment. Naturally, a stable and growing economy is a good environment in which for us to operate. That is not a direct answer, I suppose, to your particular complicated question, but hopefully it provides the context of how we work it through.
No, that's great. Thank you.
Alright, Stefan — I see your hand raised, so go ahead. Yeah, hi, this is Stefan calling from HSBC. Beyond typing questions in, I can also talk. Coming back to returns — I mean, we discussed that quite a lot last year, or at the start of this year, and you've made really solid progress. I just want to touch on two points. I'm curious about how sustainable that is, because you said that in Safety, presumably, you're earning a bit above where you should be on returns, since the business needs recapitalizing and more capacity added. So I'm wondering: how much additional capacity build-up are we actually talking about? Is the capital investment side falling a bit short right now? And is that the reason the ROIC — yeah, the return on invested capital — looks so strong at the moment?
I believe you're placing too much weight on that point, Stefan. So I don't expect it will meaningfully weigh on our capital returns moving forward. What I was attempting to do was give you some sense that at a certain point, high margins will involve some investment, but for every reason I've laid out, I'd anticipate Safety remaining at those high margins. So if I've put too much emphasis on that for you or given you a misleading impression, allow me to correct it. I don't view that as weighing on how our capital returns perform. Yeah. And what level of reinvestment are you required to make?
To give that some context, Stefan, the capex guidance we gave last year—and for this year—is GBP 35 million and GBP 38 million. So this is a capital-light business. Steve mentioned facility expansion and R&D investment to make the point that we don't want people thinking this is a story of ever-rising P&L returns. Our strategy is about sustaining high returns while delivering long-term compounding growth. No, that's understood. Thank you so much. Great. Thank you, Stefan. And I can see there are no other typed questions. So I'll just wrap up and return to the intro I gave at the start of the presentation. We're really pleased with our first-half performance—record results across both growth and returns, continued investment, and a result, a consequence of the fantastic contributions of everyone at Halma. And we sit here with confidence in the short, the medium, and the long-term future of the group. So thank you for your time and have a great day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Halma plc transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Halma plc earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.